Publication number: 20240150318
Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.
Type:
Application
Filed:
June 12, 2023
Publication date:
May 9, 2024
Inventors:
Arnab K. Chatterjee, Jian Jeffrey Chen, Elshan Nakath, Alireza Rahimi, Anil Kumar Gupta, Gennadii Grabovyi, Katy Wilson, Sourav Ghorai, Armen Nazarian, James Pedroarena, Wrickban Mazumdar, Frank Weiss, Lirui Song, Malina A. Bakowski, Laura Riva, Karen Wolff, Case W. McNamara, Thomas F. Rogers, Jacqueline Malvin, Shuangwei Li, Sean Joseph, Ashley Woods, Yuyin Liu, Neechi Okwor